anlak storytelling
All kinds
Document kinds
Loading document kinds...

Primary corpus lens for browsing and insights. Selection lives in the URL.

All formats
Orientation
Loading formats...

Landscape, portrait, square, or unknown document geometry.

Unlock
slides · global inventory

All filtered slides

Global slide inventory for the active corpus filters, with each row opening the slide detail view.

Search Insights JSON Unlock
Corpus coverage

319,975 slides

319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.

Total slides
319,975
Described
319,974
Pending
1

Slide type composition

dynamicclickable
Slide type

Showing 319,974 described slides — 100.0% of 319,975 rendered pages

+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs

Tile area is proportional to slide count. Click a category to open its subtype map.

all document kinds · all orientations
18 30 60

Slide collection

210,001-210,060 of 319,975

filter-aware
22
The slide uses a process flow diagram to show how target criteria are translated into code-based optimization and then visualized as project telemetry.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
23
The diagram uses a hub-and-spoke style flow to show data integration, model selection, generative design, and an iterative experimental feedback loop.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
24
The slide features a 3D molecular visualization and a dashboard of performance metrics (Potency, Selectivity, etc.) typical of computational drug discovery software.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
25
The scatter plot shows a Pareto-like frontier of compounds, with the AI selecting specific points (labeled 1 and 2) that are not necessarily the highest-performing in isolation but provide high information gain.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
26
The slide uses a small multiples approach to show dose-response curves across multiple patient samples, grouped by sensitivity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
27
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
28
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
29
The slide uses a stylized molecular or particle-based visual representation, likely related to the drug's mechanism of action.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
30
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a specific focus on biomarker-driven patient selection.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
31
The slide displays a heatmap of 43 patient samples showing ABS scores, signature scores, and cancer diagnoses.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
32
Includes specific p-values for Blood Mononuclear Cells and references to Fong et al (2020) and Vladimer et al (2022).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
33
The slide uses a combination of donut charts for sample sizes and bar charts for statistical significance, followed by scatter plots to visualize the inverse correlation.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
34
The slide presents two line charts with box plots showing dose-response relationships in lung cancer samples.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
35
The slide presents two key charts: a scatter plot showing the correlation between plasma exposure and target inhibition, and a line chart showing plasma concentration over time.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
36
The slide uses a stylized molecular visualization as a background element.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
37
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
38
Includes a biological pathway diagram and a honeycomb diagram for indications.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
39
The slide uses a three-column layout to define the target product profile (TPP) requirements for a CDK7 inhibitor.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
40
The table uses a color-coded heatmap (green/yellow/red) to indicate performance against criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
41
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
42
The slide uses a small multiples approach to show dose-response curves across 10 patient samples, then aggregates them into two groups to highlight differential sensitivity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
43
The right chart is a waterfall plot showing drug response scores across 53 patient samples, categorized by tumor type and responder status.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
44
The slide shows a hierarchical clustering heatmap of gene expression alongside bar charts comparing experimental vs predicted tDRS values for 30 sample patients.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
45
The slide uses a stylized abstract graphic, likely representing molecular structures or data points.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
46
TPP stands for Target Product Profile.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
47
The slide uses a traffic-light color coding system (green/yellow/red) to visualize performance metrics.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
48
The slide uses a process-flow layout to describe the company's proprietary drug discovery methodology.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
49
The slide uses a high-impact visual of a protein-ligand interaction to establish the product's identity.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
50
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
51
Includes two distinct biological diagrams/illustrations and citations for scientific literature.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
52
The slide uses a three-column layout to define the technical requirements for the drug candidate.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
53
The slide uses a color-coded heatmap (green/yellow/red/grey) to visualize performance against target product profile (TPP) criteria.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
54
The slide uses a linear process flow to describe a drug discovery pipeline.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
55
The chart illustrates a Pareto front analysis in drug discovery, highlighting the selection of compounds that are not necessarily 'optimal' by standard metrics but provide high information value.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
56
Includes statistical significance markers (*) and safety observation regarding body weight.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
57
The slide uses two distinct chart types (dot plot and line chart) to contrast the safety profiles of reversible vs irreversible LSD1 inhibitors.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
58
The chart shows tumour volume over time for various dosing regimens, with statistical significance indicated by ****.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
59
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
60
Includes a definition for MIDD at the bottom left.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
61
The background features a 3D molecular visualization, likely representing the MALT1 protein structure.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
62
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
63
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
64
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
65
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
66
The slide uses a color-coded matrix to highlight that competitors fail on UGT1A1 inhibition, while EXS73565 succeeds.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
67
The slide outlines a multi-stage pipeline: Initiate, Analyse, Evolve, 2D Models, 3D Models, and Active Learning.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
68
The slide highlights the technical methodology behind a specific drug candidate ('565) using molecular dynamics.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
69
The chart shows dose-dependent tumour volume reduction over time compared to vehicle control.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
70
The chart shows tumor volume over time (D20-D30) for various treatment groups, highlighting the superior performance of the combination therapy.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
71
Exscientia | Investor Presentation Deck | 73 slidesExscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
72
The slide uses a split-layout with status updates on the left and program highlights on the right.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Loop · Cost Of Inaction1 hit
73
This is a standard corporate contact/disclaimer slide.Exscientia | Investor Presentation Deck | 73 slides · Exscientia
Pitch deck Investor relations Beat · TeamLoop · Cost Of Inaction1 hit
01
Slide 1
First Busey | Results Presentation Deck | 41 slidesFirst Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations 1 hit
02
First Busey | Results Presentation Deck | 41 slidesFirst Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations 1 hit
03
First Busey | Results Presentation Deck | 41 slidesFirst Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations 1 hit
04
First Busey | Results Presentation Deck | 41 slidesFirst Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations 1 hit
05
Includes a map of operations across IL, IN, MO, and FL, and a table of key financial metrics from 2021-2023 YTD.First Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations Beat · ProblemLoop · Golden Circle1 hit
06
The slide uses a three-column layout to segment the business into Busey Bank, Busey Wealth Management, and FirsTech.First Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations Beat · Market SizeLoop · Golden Circle1 hit
07
The slide uses a matrix-like structure to compare four distinct geographic regions.First Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations Beat · SolutionLoop · Golden Circle1 hit
08
The slide uses a structured list format to present four key pillars of the investment thesis, followed by a summary callout at the bottom.First Busey | Results Presentation Deck | 41 slides · First Busey Corporation
Deck Investor relations Loop · Golden Circle1 hit